You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 4, 2025

Drug Price Trends for NDC 00536-7415


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00536-7415

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

00536-7415 Market Analysis and Financial Projection

Market Analysis and Price Projections for the Drug NDC: 00536-7415

Introduction

The drug with the NDC (National Drug Code) 00536-7415, which is often associated with semaglutide (brand names include Ozempic® and Wegovy®), is a key player in the pharmaceutical market, particularly in the treatment of diabetes, obesity, and related cardiovascular conditions. Here’s a detailed analysis of the market trends, price projections, and other relevant factors.

Market Context

Growing Demand for GLP-1 Agents

GLP-1 (Glucagon-Like Peptide-1) agents, such as semaglutide, have seen a significant increase in demand due to their efficacy in treating diabetes, obesity, and reducing the risk of major adverse cardiovascular events. This demand is driven by the expanding indications for these medications and their integration into standard care protocols[3].

Market Size and Growth

Current Market Value

The market for advanced parenteral drugs, which includes GLP-1 agents like semaglutide, was valued at US$ 3.24 billion in 2020. However, the broader biopharma market, which encompasses these drugs, is much larger. The biopharma market size was estimated to be over US$400 billion in 2024, with a projected CAGR of 7.56% between 2024 and 2029[2].

Growth Projections

The advanced parenteral drug market, including GLP-1 agents, is expected to grow at a CAGR of 4.3% from 2021 to 2027, reaching nearly US$ 4.35 billion by the end of 2027. The cardiovascular agent segment, which includes semaglutide, is projected to lead this growth due to increasing unhealthy lifestyle patterns and the lack of physical activity[1].

Price Projections

Drug Price Inflation

According to Vizient's summer Pharmacy Market Outlook, the overall drug price inflation rate for pharmaceuticals is estimated at 3.81% for 2025. This inflation rate is influenced by the expanding indications of previously approved medications, such as semaglutide, which has seen a 77% increase in spend since the summer 2023 Outlook[3].

Specific Price Trends for Semaglutide

Semaglutide, a key GLP-1 agent, has experienced significant price and usage growth. It is now among the top medications in terms of spend, with a notable increase in its use for treating diabetes, obesity, and cardiovascular conditions. The price of semaglutide and similar GLP-1 agents is expected to remain high due to their critical role in managing chronic conditions and the lack of generic or biosimilar alternatives in the immediate future[3].

Regional Insights

North America

North America, particularly the United States, is a significant market for advanced parenteral drugs, including semaglutide. The region is expected to have the largest market share due to the increasing acceptance of technologically advanced healthcare systems and rising patient awareness levels. Heart disease, a leading cause of death in the US, further supports the expansion of these drugs in the regional market[1].

Competitive Landscape

Key Players and Market Dynamics

The market for GLP-1 agents is competitive, with major players like Novo Nordisk (manufacturer of semaglutide) and Eli Lilly (manufacturer of tirzepatide) dominating the landscape. The competition is also influenced by the entry of new drugs and the expansion of indications for existing medications. The patent cliff, with over US$300 billion in sales at risk through 2030 due to expiring patents, is likely to drive interest in mergers and acquisitions, further shaping the market dynamics[5].

Regulatory and Technological Trends

Evolving Regulatory Frameworks

The regulatory landscape is evolving to keep pace with innovation, particularly in the biopharma and biotech sectors. This includes more flexible clinical trial designs and a greater focus on patient-centered care. These changes are expected to impact the development and approval of new drugs, including GLP-1 agents[2].

Technological Advancements

Technological advancements, such as the integration of genomics, biomarkers, and AI/ML technologies, are enhancing the development and delivery of pharmaceuticals. These innovations are expected to boost operational efficiencies and drive breakthroughs in therapeutic solutions, including those for diabetes and obesity[5].

Patient Impact and Healthcare System Preparedness

Budgetary and Operational Implications

The increasing use of high-cost therapies, including gene and cell therapies, presents budgetary, operational, and revenue challenges for healthcare systems. Providers need to prepare for these novel therapeutics by organizing cross-functionally to identify qualified patients, access treatments, and synchronize logistics for drug administration[3].

Key Takeaways

  • The market for advanced parenteral drugs, including GLP-1 agents like semaglutide, is expected to grow significantly, driven by expanding indications and increasing demand.
  • The overall drug price inflation rate is projected at 3.81% for 2025, with semaglutide experiencing a notable increase in spend.
  • North America, particularly the US, is a key market due to high healthcare spending and the prevalence of cardiovascular diseases.
  • The competitive landscape is influenced by major pharmaceutical companies and the looming patent cliff.
  • Regulatory and technological trends are shaping the development and delivery of these drugs.

FAQs

What is the current market value of the advanced parenteral drug market?

The advanced parenteral drug market was valued at US$ 3.24 billion in 2020[1].

What is the projected growth rate for the advanced parenteral drug market?

The market is expected to grow at a CAGR of 4.3% from 2021 to 2027[1].

Which segment is expected to dominate the advanced parenteral drug market?

The cardiovascular agent segment, which includes GLP-1 agents like semaglutide, is projected to lead the market growth[1].

What is the estimated drug price inflation rate for 2025?

The overall drug price inflation rate for pharmaceuticals is estimated at 3.81% for 2025[3].

How is the regulatory landscape impacting the biopharma and biotech industries?

The regulatory landscape is evolving to keep pace with innovation, including more flexible clinical trial designs and a greater focus on patient-centered care[2].

Sources

  1. Maximize Market Research: Advanced Parenteral Drug Market: Industry Analysis (2021-2027)
  2. TFS CRO: 5 Predictions for the Biopharma and Biotech Industries in 2025
  3. Vizient Inc.: Vizient projects drug price inflation at 3.81%
  4. Research and Markets: Short Bowel Syndrome Market Analysis & Forecast 2024-2034
  5. Deloitte Insights: 2025 life sciences outlook

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.